Finally, to gain further insights into the therapeutic relevance of the IFNG content in AD subgroups, the transcriptome of the low and high IFNG AD subgroups was compared to a dupilumab response signature (lesional skin at week 16 after dupilumab initiation vs. week 0), as previously described [33]. The gene discussed is IFNG; the disease is Alzheimer disease.